S100B and nervous system disorder: The first human TBI study of S100B’s value as a serum biomarker of brain injury assessment was published by Ingebrigtsen and coworkers in 1995 [75], although increased S100B levels in cerebrospinal fluid (CSF) following various neurological disorders had been previously described in patients by Sindic et al. in 1982 [165].